Scholar Rock - SRRK Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings or view top-rated stocks.

4 analysts have issued twelve-month price targets for Scholar Rock's stock. Their SRRK share price forecasts range from $19.00 to $43.00. On average, they expect the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 365.1% from the stock's current price.
View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts.

Scholar Rock's stock was trading at $24.84 on January 1st, 2022. Since then, SRRK shares have decreased by 74.0% and is now trading at $6.45.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our SRRK earnings forecast.

Scholar Rock Holding Co. (NASDAQ:SRRK) announced its quarterly earnings data on Monday, August, 8th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($1.04) by $0.02. The firm earned $1 million during the quarter. Scholar Rock had a negative trailing twelve-month return on equity of 58.30% and a negative net margin of 236.95%. The company's revenue for the quarter was down 78.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.84) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

(SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Scholar Rock's stock is owned by many different institutional and retail investors. Top institutional investors include Artal Group S.A. (24.79%), Price T Rowe Associates Inc. MD (23.90%), FMR LLC (20.72%), Millennium Management LLC (2.66%), Laurion Capital Management LP (1.59%) and State Street Corp (0.80%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier and Michael Gilman.
View institutional ownership trends.

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRRK stock can currently be purchased for approximately $6.45.

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $227.70 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis.

The company employs 145 workers across the globe.

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.